We will support your tech-transfer and scale-up process. Fast.
Scale-Up and Tech-Transfer: What our customers say
Due to the low density and poor flow characteristics of our drug substance, we experienced significant blend and content uniformity issues. By transferring our program to Quotient Sciences, the development team was able to quickly produce demo batches through multiple blending steps and roller compaction using the Gerteis Mini-Pactor. The increase in drug load from 25% to 40% was a significant improvement as we prepared for future Phase II/III trials and this ultimately benefits the patients by reducing the pill burden. We have successfully manufactured several GMP batches of tablets at various doses using a common blend.
Sean Premeau
Former Director, CMC
,
Amplyx Pharmaceuticals, a subsidiary of Pfizer Inc.
